On the HCPLive Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.
November 4th 2024
New PRO data from the INTEGUMENT-1 and –2 studies were presented at the ACAAI 2024 Meeting.
FDA Grants Dupilumab Breakthrough Therapy Designation in Atopic Dermatitis
Regeneron Pharmaceuticals, Inc. and Sanofi recently announced the US food and Drug Administration (FDA) granted Breakthrough Therapy designation to dupilumab, a fully-human monoclonal antibody, to treat adults suffering from moderate to severe atopic dermatitis (AD)who had an insufficient response to or who were not suitable for topical prescription therapy.